Compare · HYPD vs LLY
HYPD vs LLY
Side-by-side comparison of Hyperion DeFi Inc. (HYPD) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPD and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 24221.2x HYPD ($48.6M).
- Over the past year, HYPD is down 60.5% and LLY is up 56.5% - LLY leads by 117.0 points.
- LLY has been more active in the news (25 items in the past 4 weeks vs 7 for HYPD).
- LLY has more recent analyst coverage (25 ratings vs 2 for HYPD).
- Company
- Hyperion DeFi Inc.
- Eli Lilly and Company
- Price
- $2.87-8.60%
- $1257.32+0.45%
- Market cap
- $48.6M
- $1.18T
- 1M return
- -17.29%
- +9.10%
- 1Y return
- -60.52%
- +56.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 7
- 25
- Recent ratings
- 2
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest HYPD
- Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.
- Hyperion DeFi Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization
- Chief Financial Officer Knox David R. covered exercise/tax liability with 19,563 shares, decreasing direct ownership by 6% to 287,556 units (SEC Form 4) (withholding tax)
- Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid
- Hyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem
- Hyperion DeFi Supports DoubleZero Edge in Launching the Fastest Commercially Available Hyperliquid Data Feeds
- Hyperion DeFi Raises Guidance and Announces $20M Share Repurchase Program
- Officer Jung Hyunsu covered exercise/tax liability with 40,000 shares, decreasing direct ownership by 3% to 1,345,676 units (SEC Form 4) to satisfy withholding tax
- SEC Form 10-Q filed by Hyperion DeFi Inc.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease